KSQ Therapeutics Stock
Drug discovery company
About KSQ Therapeutics Stock
KSQ Therapeutics states that it is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by a proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a more comprehensive understanding of disease biology. The quality of these insights enables their scientists to identify and validate high-confidence, patient-tailored drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
VP, Head of Chemistry and Drug Design
René M. Lemieux
Sr. Director, Head of Corporate Development
Managing Director & CEO